Latest Insider Transactions at Natera, Inc. (NTRA)
This section provides a real-time view of insider transactions for Natera, Inc. (NTRA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Natera, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Natera, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 24
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
946
-0.43%
|
$162,712
$172.12 P/Share
|
|
Jan 23
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
495
-0.45%
|
$84,645
$171.09 P/Share
|
|
Jan 22
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
21,228
-6.3%
|
$3,566,304
$168.46 P/Share
|
|
Jan 22
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
24,861
-7.51%
|
$4,176,648
$168.45 P/Share
|
|
Jan 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+1.11%
|
-
|
|
Jan 22
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
SELL
Open market or private sale
|
Direct |
25,931
-9.57%
|
$4,356,408
$168.45 P/Share
|
|
Jan 22
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
78,553
-11.35%
|
$13,196,904
$168.46 P/Share
|
|
Jan 22
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
22,039
-4.6%
|
$3,702,552
$168.45 P/Share
|
|
Jan 22
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
971
-0.18%
|
$163,128
$168.43 P/Share
|
|
Jan 21
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,145
+0.84%
|
-
|
|
Jan 21
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
1,775
+0.51%
|
-
|
|
Jan 21
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
644
+0.27%
|
-
|
|
Jan 21
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
144
+0.05%
|
-
|
|
Jan 20
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,522
+1.12%
|
-
|
|
Jan 20
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
3,386
+0.97%
|
-
|
|
Jan 20
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
856
+0.36%
|
-
|
|
Jan 20
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
191
+0.07%
|
-
|
|
Jan 16
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
39,730
+23.01%
|
-
|
|
Jan 16
2025
|
Michael Burkes Brophy CHIEF FINANCIAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
24,348
+20.71%
|
-
|
|
Jan 16
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Grant, award, or other acquisition
|
Direct |
101,812
+22.99%
|
-
|
|
Jan 16
2025
|
Steven Leonard Chapman CEO AND PRESIDENT |
BUY
Exercise of conversion of derivative security
|
Direct |
54,175
+18.47%
|
-
|
|
Jan 16
2025
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
54,316
+10.54%
|
-
|
|
Jan 16
2025
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
48,548
+9.43%
|
-
|
|
Jan 16
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
24,832
+9.44%
|
-
|
|
Jan 16
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
13,696
+6.03%
|
-
|
|
Jan 16
2025
|
Jonathan Sheena |
BUY
Grant, award, or other acquisition
|
Direct |
4,966
+1.86%
|
-
|
|
Jan 16
2025
|
Jonathan Sheena |
BUY
Exercise of conversion of derivative security
|
Direct |
3,043
+1.17%
|
-
|
|
Jan 08
2025
|
Daniel Rabinowitz SEC. AND CHIEF LEGAL OFFICER |
SELL
Open market or private sale
|
Direct |
6,223
-3.02%
|
$1,089,025
$175.3 P/Share
|
|
Jan 02
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
3,000
-1.09%
|
$477,000
$159.72 P/Share
|
|
Jan 02
2025
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.35%
|
$429,300
$159.68 P/Share
|
|
Dec 23
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
2,428
-0.68%
|
$383,624
$158.62 P/Share
|
|
Dec 23
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
SELL
Open market or private sale
|
Direct |
669
-0.29%
|
$105,702
$158.78 P/Share
|
|
Dec 23
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Bona fide gift
|
Direct |
81
-0.07%
|
-
|
|
Dec 20
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
4,719
+1.95%
|
-
|
|
Dec 20
2024
|
John Fesko PRESIDENT, CHIEF BUS. OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
1,675
+1.44%
|
-
|
|
Dec 19
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Bona fide gift
|
Direct |
125
-0.11%
|
-
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
2,148
-0.91%
|
$358,716
$167.09 P/Share
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Indirect |
852
-1.79%
|
$142,284
$167.07 P/Share
|
|
Dec 18
2024
|
Jonathan Sheena |
SELL
Open market or private sale
|
Direct |
2,700
-0.35%
|
$450,900
$167.12 P/Share
|
|
Dec 13
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Direct |
160,000
-1.28%
|
$26,560,000
$166.45 P/Share
|
|
Dec 10
2024
|
Rowan E Chapman |
SELL
Open market or private sale
|
Direct |
1,767
-22.17%
|
$300,390
$170.24 P/Share
|
|
Dec 09
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
SELL
Open market or private sale
|
Direct |
4,858
-4.06%
|
$806,428
$166.59 P/Share
|
|
Dec 09
2024
|
Solomon Moshkevich PRESIDENT, CLINICALDIAGNOSTICS |
BUY
Grant, award, or other acquisition
|
Direct |
9,075
+3.7%
|
$90,750
$10.15 P/Share
|
|
Dec 05
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
BUY
Exercise of conversion of derivative security
|
Direct |
68,496
+2.62%
|
$342,480
$5.4 P/Share
|
|
Dec 02
2024
|
Roelof Botha Director |
SELL
Open market or private sale
|
Indirect |
87,473
-1.37%
|
$14,695,464
$168.7 P/Share
|
|
Nov 26
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
2,000
-0.78%
|
$328,000
$164.35 P/Share
|
|
Nov 25
2024
|
Matthew Rabinowitz EXECUTIVE CHAIRMAN |
SELL
Open market or private sale
|
Indirect |
2,000
-0.76%
|
$336,000
$168.91 P/Share
|
|
Nov 19
2024
|
Gail Boxer Marcus |
SELL
Open market or private sale
|
Direct |
9,682
-28.45%
|
$1,549,120
$160.18 P/Share
|
|
Nov 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
4,628
-0.49%
|
$680,316
$147.3 P/Share
|
|
Nov 15
2024
|
Steven Leonard Chapman CEO AND PRESIDENT |
SELL
Open market or private sale
|
Direct |
100
-0.05%
|
$14,600
$146.35 P/Share
|